ClinicalTrials.gg
Active, not recruitingNCT06441994Alpha-PS1Updated Jul 28, 2026

Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate Cancer

A Phase 1 interventional study of PSW-1025 in Prostate Cancer, sponsored by Osaka University. Active, not recruiting at 1 site in Japan. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Osaka University · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 133 studies in Prostatic Neoplasms with a site in Japan — 36 open to participants now, 69 under way, 30 of them phase 3. Prostatic Neoplasms · Japan.

Planned enrollment
106th of 116
15 · median 351
Started
2024
with 13 others
Phase 1
28 of 133
8 open now
Primary completion
2027-03
later than 24 of 68 live
Registered
102nd of 133
by date

Among the 133 studies in Prostatic Neoplasms with a site in Japan, this one is the 106th largest by planned enrollment of the 116 interventional ones that give a count, is one of 14 that started in 2024, is one of 28 in phase 1, reaches primary completion later than 24 of the 68 other live ones, and was the 102nd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

36 of the 133 studies in Prostatic Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Prostatic Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

PSW-1025 is administered intravenously to patients with castration-resistant prostate cancer to evaluate its tolerability, safety, pharmacokinetics, absorbed dose, and efficacy, as well as to determine the recommended dose for Phase II.

Read the detailed description

PSW-1025 is administered intravenously to patients with castration-resistant prostate cancer to evaluate its tolerability, safety, pharmacokinetics, absorbed dose, and efficacy, as well as to determine the recommended dose for Phase II. PSW-1025 ([At-211]PSMA-5) is an alpha-ray-emitting drug labeled with Astatine (At-211) that targets PSMA (Prostate Specific Membrane Antigen).

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Astatine (At-211)
  • Targeted alpha therapy
  • PSMA (Prostate Specific Membrane Antigen)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with progressive castration-resistant prostate cancer who meet the following conditions (1) and (2) (1) Patients with progressive increase of serum Prostate-Specific Antigen (PSA) (>=2ng/mL, three consecutive increases at least one week apart, and two increases of more than 50% from the lowest value), or with the tumor growth or appearance of new lesions detected by imaging studies (2) Patients with the serum testosterone at castration level (\< 50ng/dL)
  2. Patients who meet the following conditions (1) and (2), resistant to standard treatment or not indicated for the generally approved standard treatments (1) Patients who have received at least one of the following treatments

    • Inhibitors of androgen receptor signaling (enzalutamide, apalutamide, dalortamide, etc.)
    • Inhibitors of Cytochrome P450 17 (CYP 17) (abiraterone acetate) (2) Patients previously treated with the taxane-based chemotherapy (docetaxel or cabazitaxel) or not adapted for the taxane-based chemotherapy (including refusal cases)* * Targeting for the patients who have received cabazitaxel therapy after docetaxel therapy, or patients for whom cabazitaxel therapy was not indicated (including refusal cases) after docetaxel therapy, or patients for whom both docetaxel therapy and cabazitaxel therapy were not indicated (including refusal cases)
  3. Patients aged 18 years or older at the time of consent acquisition
  4. Patients with stable general condition with PS (Performance status) of 0 to 2 in (Eastern Cooperative Oncology Group)
  5. Patients who can be expected to survive for 6 months or more, judging from clinical symptoms and medical examination findings
  6. Patients without or with controlled symptomatic
  7. Patients with no abnormal findings in , respiratory rate, and blood oxygen saturation within 30 days before the enrollment
  8. Patients whose laboratory values within 30 days before the enrollment are within the range specified in the protocol
  9. Patients who can use appropriate during the clinical trial period according to the protocol
  10. Patients who thoroughly listened to the explanation of the clinical trial, agreed to the various study procedures outlined in the clinical trial protocol and signed the consent document

Exclusion criteria

Exclusion Criteria:

  1. Patients who received systemic antitumor therapy (e.g. chemotherapy, immunotherapy, biologic therapy such as monoclonal antibodies, excluding androgen receptor signaling inhibitors) within 4 weeks before enrollment
  2. Patients who received radium chloride (Radium, 223Ra) or 177Lu (Lutetium)-PSMA-617 within 6 months before registration
  3. Patients currently receiving treatment with other cytotoxic chemotherapy, immunotherapy, radioligand therapy, poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, AKT inhibitors
  4. Patients with active double cancer (simultaneous double cancer and ectopic double cancer with a disease-free period of 5 years or less)
  5. Patients who received other drugs within 5 weeks prior to enrollment
  6. Patients with uncontrollable active infections
  7. surface antigen positive, Virus antibody positive (patients with HCV-RNA level below the limit of detection can be registered) or antibody positive patients
  8. Patients with mental illness or psychiatric symptoms who are judged to be difficult to participate in clinical trials
  9. Other patients who are judged to be inappropriate by the investigator, etc.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Administration arm

    Drug: PSW-1025

Interventions

  • DrugPSW-1025

    PSMA (prostate specific membrane antigen)-targeted alpha therapy drug labeled with Astatine (At-211)

06

What researchers measure

Primary outcomes

  1. Treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: until 6 months after administration

  2. Dose Limiting Toxicity

    Time frame: within 4 weeks after single administration

Secondary outcomes

  1. Number of participants with adverse events and their details

    Time frame: until 6 months after administration

  2. Blood pressure (mmHg) and heart rate (bpm)

    Time frame: until 6 months after administration

  3. Symptoms of the participants

    Time frame: until 6 months after administration

  4. Hematological tests (blood cell counts)

    Time frame: until 6 months after administration

  5. Urine tests (occult blood and urine protein)

    Time frame: until 6 months after administration

  6. Electrocorticogram

    Time frame: until 6 months after administration

  7. Prostate-Specific Antigen (PSA) (ng/ml)

    Time frame: until 6 months after administration

  8. Tumor size on CT (mm)

    Time frame: until 6 months after administration

  9. Excretion rates in urine, feces, and breath (%injected dose)

    Time frame: until 24 hours after administration

  10. Absorbed doses in major organs (Gy)

    Time frame: until 24 hours after administration

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Mar 2027, 34 months after the start.

Of 243 non-industry phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 76. This study's planned 34 months is below that.

Counting every sponsor, half of 455 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2024
First posted
Jun 4, 2024
StartActual
May 24, 2024
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06441994
Lead sponsor
Osaka University
Collaborators
Japan Agency for Medical Research and Development
Responsible party
Tadashi Watabe (Associate Professor, Osaka University) — Principal investigator
First posted
Jun 4, 2024
Start date
May 24, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jul 28, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion